<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567539</url>
  </required_header>
  <id_info>
    <org_study_id>1394</org_study_id>
    <nct_id>NCT02567539</nct_id>
  </id_info>
  <brief_title>Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma</brief_title>
  <official_title>Phase II Study of Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to evaluate efficacy and safety of re-irradiation for patients with&#xD;
      recurrent high grade gliomas after other treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators designed this study of a re-irradiation with single radiosurgery or&#xD;
      hypofractionated intensity modulated radiation therapy (IMRT) with or without temozolomide.&#xD;
&#xD;
      Objective of the study is evaluating efficacy and safety of re-irradiation for patients with&#xD;
      recurrent high grade gliomas after other treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 27, 2015</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free of participants</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival of participants</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of radionecrosis</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire assessment of neurocognitive function</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Recurrent High Grade Glioma</condition>
  <arm_group>
    <arm_group_label>Recurrent high grade glioma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMRT with or without radiosensitive therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT with or without radiosensitive therapy</intervention_name>
    <description>Re-irradiation with hypofractionated intensity modulated radiation therapy (IMRT), using VMAT RapidArc</description>
    <arm_group_label>Recurrent high grade glioma</arm_group_label>
    <other_name>Hypofractionated Stereotactic Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiosensitive therapy</intervention_name>
    <description>Radiosensitive therapy with Temozolomide</description>
    <arm_group_label>Recurrent high grade glioma</arm_group_label>
    <other_name>Chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Karnosky performance status (KPS) ≥70&#xD;
&#xD;
          -  Patients aged &gt;70 years with KPS ≥80&#xD;
&#xD;
          -  Histopathologically confirmed grade III-IV glioma&#xD;
&#xD;
          -  Estimated survival ≥ 3 months&#xD;
&#xD;
          -  Any Tumor volume&#xD;
&#xD;
          -  Unifocal tumor&#xD;
&#xD;
          -  Interval time from previous radiotherapy ≥ 6mesi&#xD;
&#xD;
          -  Normal liver, Kidney and bone marrow function&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  KPS &lt; 70&#xD;
&#xD;
          -  Multifocal tumor&#xD;
&#xD;
          -  Other primary cancer&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piera Navarria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Navarria P, Ascolese AM, Tomatis S, Reggiori G, Clerici E, Villa E, Maggi G, Bello L, Pessina F, Cozzi L, Scorsetti M. Hypofractionated Stereotactic Radiation Therapy in Recurrent High-Grade Glioma: A New Challenge. Cancer Res Treat. 2016 Jan;48(1):37-44. doi: 10.4143/crt.2014.259. Epub 2015 Feb 23.</citation>
    <PMID>25761491</PMID>
  </results_reference>
  <results_reference>
    <citation>Scorsetti M, Navarria P, Pessina F, Ascolese AM, D'Agostino G, Tomatis S, De Rose F, Villa E, Maggi G, Simonelli M, Clerici E, Soffietti R, Santoro A, Cozzi L, Bello L. Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma. BMC Cancer. 2015 Jun 30;15:486. doi: 10.1186/s12885-015-1488-2.</citation>
    <PMID>26118437</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 28, 2015</study_first_submitted>
  <study_first_submitted_qc>October 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Michele Tedeschi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

